BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 10405717)

  • 1. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET.
    Shulkin BL; Thompson NW; Shapiro B; Francis IR; Sisson JC
    Radiology; 1999 Jul; 212(1):35-41. PubMed ID: 10405717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pheochromocytomas that do not accumulate metaiodobenzylguanidine: localization with PET and administration of FDG.
    Shulkin BL; Koeppe RA; Francis IR; Deeb GM; Lloyd RV; Thompson NW
    Radiology; 1993 Mar; 186(3):711-5. PubMed ID: 8430179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy.
    Shulkin BL; Hutchinson RJ; Castle VP; Yanik GA; Shapiro B; Sisson JC
    Radiology; 1996 Jun; 199(3):743-50. PubMed ID: 8637999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MIBG and FDG PET findings in a patient with malignant pheochromocytoma: a significant discrepancy.
    Ezuddin S; Fragkaki C
    Clin Nucl Med; 2005 Aug; 30(8):579-81. PubMed ID: 16024963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.
    Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Ling A; Eisenhofer G; Adams KT; Solis D; Lenders JW; Pacak K
    J Clin Oncol; 2007 Jun; 25(16):2262-9. PubMed ID: 17538171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Case of 131I-meta-iodobenzylguanidine (MIBG) scintigraphy-negative and 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)-positive pheochromocytoma].
    Jotoku M; Okura T; Nagao T; Enomoto D; Irita J; Miyoshi K; Kurata M; Fukuoka T; Higaki J
    Nihon Jinzo Gakkai Shi; 2009; 51(5):563-8. PubMed ID: 19715165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma.
    Mann GN; Link JM; Pham P; Pickett CA; Byrd DR; Kinahan PE; Krohn KA; Mankoff DA
    Ann Surg Oncol; 2006 Feb; 13(2):187-97. PubMed ID: 16418883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
    J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brown fat imaging with (18)F-6-fluorodopamine PET/CT, (18)F-FDG PET/CT, and (123)I-MIBG SPECT: a study of patients being evaluated for pheochromocytoma.
    Hadi M; Chen CC; Whatley M; Pacak K; Carrasquillo JA
    J Nucl Med; 2007 Jul; 48(7):1077-83. PubMed ID: 17574980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Havekes B; Eisenhofer G; Martiniova L; Adams KT; Pacak K
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4757-67. PubMed ID: 19864450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDOPA PET Compared With 123I-Metaiodobenzylguanidine Scintigraphy and 18F-FDG PET in Secreting Sporadic Pheochromocytoma.
    Lugat A; Drui D; Mirallié E; Kraeber-Bodéré F; Ansquer C
    Clin Nucl Med; 2019 Sep; 44(9):738-740. PubMed ID: 31306205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG PET in the evaluation of phaeochromocytoma: a correlative study with MIBG scintigraphy and Ki-67 proliferative index.
    Lin M; Wong V; Yap J; Jin R; Leong P; Campbell P
    Clin Imaging; 2013; 37(6):1084-8. PubMed ID: 24035263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of metastatic lesions from malignant pheochromocytoma and paraganglioma with diffusion-weighted magnetic resonance imaging: comparison with 18F-FDG positron emission tomography and 123I-MIBG scintigraphy.
    Takano A; Oriuchi N; Tsushima Y; Taketomi-Takahashi A; Nakajima T; Arisaka Y; Higuchi T; Amanuma M; Endo K
    Ann Nucl Med; 2008 Jun; 22(5):395-401. PubMed ID: 18600417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography with 18F-fluorodeoxyglucose is a useful tool for the diagnosis of pheochromocytomas without distant metastasis, where malignancy is suspected on the basis of histopathologic analysis.
    Kikuchi F; Imachi H; Murao K; Ohyama T; Miyai Y; Kushida Y; Haba R; Kakehi Y; Ishida T
    Am J Med Sci; 2010 Aug; 340(2):160-3. PubMed ID: 20693835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
    Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
    Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
    Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses.
    Maurea S; Klain M; Mainolfi C; Ziviello M; Salvatore M
    J Nucl Med; 2001 Jun; 42(6):884-92. PubMed ID: 11390552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
    Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
    J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging characterization of non-hypersecreting adrenal masses. Comparison between MR and radionuclide techniques.
    Maurea S; Caracò C; Klain M; Mainolfi C; Salvatore M
    Q J Nucl Med Mol Imaging; 2004 Sep; 48(3):188-97. PubMed ID: 15499292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging.
    Havekes B; Lai EW; Corssmit EP; Romijn JA; Timmers HJ; Pacak K
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):419-29. PubMed ID: 19088695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.